Drug intelligence / Profile preview

SNP234

Development stage: Preclinical
Lead developer: SciNeuro Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral (likely Intravenous Or Subcutaneous; Specific Route Not Detailed But Typical For Monoclonal Antibodies)[1]

Overview

SNP234 is a monoclonal antibody developed by SciNeuro Pharmaceuticals for the treatment of Alzheimer's disease. It functions as an anti-amyloid antibody designed to inhibit amyloid beta-protein aggregation and promote removal of amyloid plaques from the brain. The drug targets the beta amyloid A4 protein (APP), modulating its activity to address pathological features associated with Alzheimer's disease. As of March 2025, it remains in preclinical development and has not yet entered clinical trials[1][2].

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on SNP234.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNP234.

Explore the full profile